PipelineActive studySynthetic mock data

Drug development

Candidates in development, dose-escalation cohorts, and recent toxicity signals.

Candidates by phase

4 active programs

Discovery

IND-enabling

VNQ-512 · CLDN18.2

Phase I

VNQ-218 · HER3

Phase Ib

VNQ-104 · FGFR2/3
VNQ-330 · PD-1 × LAG-3

Phase II

Phase III

VNQ-104Small moleculePhase Ib

Target: FGFR2/3

Cholangiocarcinoma · next milestone: MTD declaration Q3

2 tox flagsOpen binder

Dose levels

50 mg QD

cleared

Cohort N 6

DLTs 0

100 mg QD

cleared

Cohort N 6

DLTs 1

150 mg QD

expanding

Cohort N 9

DLTs 1

200 mg QD

open

Cohort N 0

DLTs 0

VNQ-218ADCPhase I

Target: HER3

Pancreatic, gastric · next milestone: Cohort review w/ DSMB

4 tox flagsOpen binder

Dose levels

1.6 mg/kg

cleared

Cohort N 3

DLTs 0

3.2 mg/kg

cleared

Cohort N 6

DLTs 1

4.8 mg/kg

halted

Cohort N 6

DLTs 2

6.4 mg/kg

open

Cohort N 0

DLTs 0

VNQ-330BispecificPhase Ib

Target: PD-1 × LAG-3

Hepatocellular · next milestone: Phase II protocol draft

1 tox flagOpen binder

Dose levels

200 mg q3w

cleared

Cohort N 6

DLTs 0

400 mg q3w

cleared

Cohort N 6

DLTs 1

800 mg q3w

expanding

Cohort N 12

DLTs 1

VNQ-512AntibodyIND-enabling

Target: CLDN18.2

Gastric · next milestone: IND submission Q2

Open binder

Pre-clinical — no dose levels assigned yet

Recent toxicity events

Last 14 days · grade ≥ 1

Date	Candidate	Case	Grade	Term	Resolved
2026-04-22	VNQ-218	E0210-HCC-007	G3	Neutropenia	Active
2026-04-20	VNQ-104	P1b-CHO-019	G2	Hyperphosphatemia	Resolved
2026-04-18	VNQ-218	E0210-HCC-009	G3	ILD / pneumonitis	Active
2026-04-16	VNQ-330	F4407-LIV-208	G2	Hepatic enzyme increased	Resolved
2026-04-15	VNQ-104	P1b-CHO-024	G1	Diarrhea	Resolved